Main Management ETF Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Main Management ETF Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,962	Closed	-$2.34M	–	121
2025 Q4	$2.34M	Buy	10,962 +112	+1%	+$23.1K	0.08%	40
2025 Q3	$2.16M	Buy	10,850 +4,986	+85%	+$930K	0.08%	47
2025 Q2	$1.01M	Buy	5,864 +96	+2%	+$15.6K	0.04%	86
2025 Q1	$899K	Buy	5,768 +72	+1%	+$10.3K	0.04%	77
2024 Q4	$784K	Sell	5,696 -512	-8%	-$67.3K	0.04%	97
2024 Q3	$927K	Buy	+6,208	New	+$838K	0.04%	75

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Main Management ETF Advisors's ASND Position: Q1 2026 in Review

Main Management ETF Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 10,962 shares — an estimated $2.34M sold.

Main Management ETF Advisors first reported a position in ASND in Q3 2024 and held it in 6 quarters. The position peaked at $2.34M in Q4 2025. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Main Management ETF Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Main Management ETF Advisors sold 10,962 Ascendis Pharma A/S shares in Q1 2026, an estimated $2.34M.
Main Management ETF Advisors first reported a position in Ascendis Pharma A/S in Q3 2024 and held it in 6 quarters.
Main Management ETF Advisors's Ascendis Pharma A/S position peaked at $2.34M in Q4 2025.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Main Management ETF Advisors's 13F filing for Q1 2026, filed 15 May 2026.